Results 51 to 60 of about 69,629 (300)

Levodopa versus non-levodopa brain language fMRI in Parkinson’s disease [PDF]

Einstein (São Paulo), 2012
Objective: To identify the effect of levodopa in language areas inParkinson’s disease patients. Methods: We evaluated 50 patientswith mild to moderate Parkinson’s disease, age and gender pairedto 47 healthy volunteers.
Paula Ricci Arantes, Heloise Helena Gobato, Bárbara Bordegatto Davoglio, Maria Ângela Maramaldo Barreiros, André Carvalho Felício, Orlando Graziani Povoas Barsottini, Luiz Augusto Franco de Andrade, Edson Amaro Junior   +7 more
doaj  

Costs of Parkinson's Disease and Antiparkinsonian Pharmacotherapy: An Italian Cohort Study [PDF]

, 2010
Objective: Antiparkinsonian pharmacotherapy is costly and the determinants of drug costs in Parkinson's disease (PD) have been poorly investigated. The objective of this study was to investigate the costs of PD and antiparkinsonian drugs in an Italian ...
Balzer-Geldsetzer, Monika, Barone, Paolo, Bötzel, Kai, Campenhausen, Sonja von, Dodel, Richard, Eggert, Karla, Longo, Katia, Oertel, Wolfgang H., Reese, Jens P., Spiga, Giuseppe, Winter, Yaroslav   +10 more
core   +1 more source

CSF Monoamine Metabolites and Cognitive Trajectory in Early Parkinson's Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Imaging and postmortem studies indicate that abnormalities in monoaminergic neurotransmission contribute to cognitive impairment in Parkinson's disease (PD). However, it remains uncertain if cerebrospinal fluid (CSF) monoamine metabolites can serve as biomarkers of cognitive decline in early PD.
Jing‐Yu Shao, Rong Li, Yu‐Xiang Jiao, Kai Ma, Hong‐Qi Yang, Zheng‐Yu Sun, Jie‐Wen Zhang, Shuai Chen   +7 more
wiley   +1 more source

Evaluating the impact of adjunctive istradefylline on the cumulative dose of levodopa-containing medications in Parkinson’s disease: study protocol for the ISTRA ADJUST PD randomized, controlled study

BMC Neurology, 2022
Background Levodopa remains the most effective symptomatic treatment for Parkinson’s disease (PD) more than 50 years after its clinical introduction. However, the onset of motor complications can limit pharmacological intervention with levodopa, which ...
Taku Hatano, Osamu Kano, Renpei Sengoku, Asako Yoritaka, Keisuke Suzuki, Noriko Nishikawa, Yohei Mukai, Kyoichi Nomura, Norihito Yoshida, Morinobu Seki, Miho Kawabe Matsukawa, Hiroo Terashi, Katsuo Kimura, Jun Tashiro, Shigeki Hirano, Hidetomo Murakami, Hideto Joki, Tsuyoshi Uchiyama, Hideki Shimura, Kotaro Ogaki, Jiro Fukae, Yoshio Tsuboi, Kazushi Takahashi, Toshimasa Yamamoto, Naotake Yanagisawa, Hiroshi Nagayama   +25 more
doaj   +1 more source

A review of neuroleptic malignant syndrome : incidence and features in Malta [PDF]

, 1995
This paper describes Malta’s first sample of Neuroleptic Malignant Syndrome (NMS) and reviews the current literature. A retrospective sample of all diagnosed cases of NMS was reviewed using Pope’s (1986) criteria. Twelve cases were identified yielding an
Grech, Anton, Saliba, Joseph R.
core  

Mortality in Parkinson's disease : A systematic review and meta-analysis [PDF]

, 2014
© 2014 International Parkinson and Movement Disorder Society.Peer reviewedPublisher ...
Greenland S, Harbord RM, Laupacis A, Nobrega F   +3 more
core   +1 more source

Non‐Invasive Brain Targeted Delivery of Cannabidiol for Alleviating Neuroinflammatory Disease

Advanced Materials, EarlyView.
The glucose‐functionalized nanoparticles (GNPs) are developed for the brain‐targeted delivery of cannabidiol (CBD). GNPs bypass the blood‐brain barrier (BBB) via glucose transporter‐1 (GLUT‐1) and release CBD in response to reactive oxygen species (ROS).
Yibin Wang, Yundong Li, Xin Wang, Yaning Hou, Wei Deng, Meng Zheng, Yan Zou, Bingyang Shi   +7 more
wiley   +1 more source

Optimizing levodopa therapy for Parkinson’s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective

Neuropsychiatric Disease and Treatment, 2008
David J BrooksDivision of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, UKAbstract: After 40 years of clinical experience, levodopa remains the gold standard treatment for Parkinson’s disease (PD) despite ...
David J Brooks
doaj  

Levodopa acts centrally to induce an antinociceptive action against colonic distension through activation of D2 dopamine receptors and the orexinergic system in the brain in conscious rats

Journal of Pharmacological Sciences, 2016
Levodopa possesses antinociceptive actions against several somatic pain conditions. However, we do not know at this moment whether levodopa is also effective to visceral pain.
Toshikatsu Okumura, Tsukasa Nozu, Shima Kumei, Kaoru Takakusaki, Saori Miyagishi, Masumi Ohhira   +5 more
doaj   +1 more source

Incidence of mild cognitive impairment and dementia in Parkinson's disease: The Parkinson's disease cognitive impairment study [PDF]

, 2019
Background: Cognitive impairment in Parkinson's disease (PD) includes a spectrum varying from Mild Cognitive Impairment (PD-MCI) to PD Dementia (PDD). The main aim of the present study is to evaluate the incidence of PD-MCI, its rate of progression to ...
Baschi R., Cicero C. E., Davi M., Luca A., Monastero R., Mostile G., Nicoletti A., Pilati L., Restivo V., Zappia M.   +9 more
core   +1 more source